197 related articles for article (PubMed ID: 31026260)
1. Vaccination with a chikungunya virus-like particle vaccine exacerbates disease in aged mice.
Arévalo MT; Huang Y; Jones CA; Ross TM
PLoS Negl Trop Dis; 2019 Apr; 13(4):e0007316. PubMed ID: 31026260
[TBL] [Abstract][Full Text] [Related]
2. Co-Immunization With CHIKV VLP and DNA Vaccines Induces a Promising Humoral Response in Mice.
Zhao Z; Deng Y; Niu P; Song J; Wang W; Du Y; Huang B; Wang W; Zhang L; Zhao P; Tan W
Front Immunol; 2021; 12():655743. PubMed ID: 33868299
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of recombinant E2 protein-based and whole-virus inactivated candidate vaccines against chikungunya virus.
Kumar M; Sudeep AB; Arankalle VA
Vaccine; 2012 Sep; 30(43):6142-9. PubMed ID: 22884660
[TBL] [Abstract][Full Text] [Related]
4. Effect of a Chikungunya Virus-Like Particle Vaccine on Safety and Tolerability Outcomes: A Randomized Clinical Trial.
Chen GL; Coates EE; Plummer SH; Carter CA; Berkowitz N; Conan-Cibotti M; Cox JH; Beck A; O'Callahan M; Andrews C; Gordon IJ; Larkin B; Lampley R; Kaltovich F; Gall J; Carlton K; Mendy J; Haney D; May J; Bray A; Bailer RT; Dowd KA; Brockett B; Gordon D; Koup RA; Schwartz R; Mascola JR; Graham BS; Pierson TC; Donastorg Y; Rosario N; Pape JW; Hoen B; Cabié A; Diaz C; Ledgerwood JE;
JAMA; 2020 Apr; 323(14):1369-1377. PubMed ID: 32286643
[TBL] [Abstract][Full Text] [Related]
5. Expression and Characterization of Yeast Derived Chikungunya Virus Like Particles (CHIK-VLPs) and Its Evaluation as a Potential Vaccine Candidate.
Saraswat S; Athmaram TN; Parida M; Agarwal A; Saha A; Dash PK
PLoS Negl Trop Dis; 2016 Jul; 10(7):e0004782. PubMed ID: 27399001
[TBL] [Abstract][Full Text] [Related]
6. Liposomal Delivery of the RNA Genome of a Live-Attenuated Chikungunya Virus Vaccine Candidate Provides Local, but Not Systemic Protection After One Dose.
Abeyratne E; Tharmarajah K; Freitas JR; Mostafavi H; Mahalingam S; Zaid A; Zaman M; Taylor A
Front Immunol; 2020; 11():304. PubMed ID: 32194557
[TBL] [Abstract][Full Text] [Related]
7. A single dose of ChAdOx1 Chik vaccine induces neutralizing antibodies against four chikungunya virus lineages in a phase 1 clinical trial.
Folegatti PM; Harrison K; Preciado-Llanes L; Lopez FR; Bittaye M; Kim YC; Flaxman A; Bellamy D; Makinson R; Sheridan J; Azar SR; Campos RK; Tilley M; Tran N; Jenkin D; Poulton I; Lawrie A; Roberts R; Berrie E; Rossi SL; Hill A; Ewer KJ; Reyes-Sandoval A
Nat Commun; 2021 Jul; 12(1):4636. PubMed ID: 34330906
[TBL] [Abstract][Full Text] [Related]
8. A novel MVA vectored Chikungunya virus vaccine elicits protective immunity in mice.
Weger-Lucarelli J; Chu H; Aliota MT; Partidos CD; Osorio JE
PLoS Negl Trop Dis; 2014 Jul; 8(7):e2970. PubMed ID: 25058320
[TBL] [Abstract][Full Text] [Related]
9. Adenoviral-Vectored Mayaro and Chikungunya Virus Vaccine Candidates Afford Partial Cross-Protection From Lethal Challenge in A129 Mouse Model.
Campos RK; Preciado-Llanes L; Azar SR; Kim YC; Brandon O; López-Camacho C; Reyes-Sandoval A; Rossi SL
Front Immunol; 2020; 11():591885. PubMed ID: 33224148
[TBL] [Abstract][Full Text] [Related]
10. Chikungunya virus-like particles are more immunogenic in a lethal AG129 mouse model compared to glycoprotein E1 or E2 subunits.
Metz SW; Martina BE; van den Doel P; Geertsema C; Osterhaus AD; Vlak JM; Pijlman GP
Vaccine; 2013 Dec; 31(51):6092-6. PubMed ID: 24099875
[TBL] [Abstract][Full Text] [Related]
11. A measles virus-based vaccine induces robust chikungunya virus-specific CD4
Schmitz KS; Comvalius AD; Nieuwkoop NJ; Geers D; Weiskopf D; Ramsauer K; Sette A; Tschismarov R; de Vries RD; de Swart RL
Vaccine; 2023 Oct; 41(43):6495-6504. PubMed ID: 37726181
[TBL] [Abstract][Full Text] [Related]
12. A Virus-Like Particle Vaccine Elicits Broad Neutralizing Antibody Responses in Humans to All Chikungunya Virus Genotypes.
Goo L; Dowd KA; Lin TY; Mascola JR; Graham BS; Ledgerwood JE; Pierson TC
J Infect Dis; 2016 Nov; 214(10):1487-1491. PubMed ID: 27655868
[TBL] [Abstract][Full Text] [Related]
13. Analysis of Humoral Immune Responses in Chikungunya Virus (CHIKV)-Infected Patients and Individuals Vaccinated With a Candidate CHIKV Vaccine.
Henss L; Yue C; Von Rhein C; Tschismarov R; Lewis-Ximenez LL; Dölle A; Baylis SA; Schnierle BS
J Infect Dis; 2020 Apr; 221(10):1713-1723. PubMed ID: 31828322
[TBL] [Abstract][Full Text] [Related]
14. Vaccine-Induced Skewing of T Cell Responses Protects Against Chikungunya Virus Disease.
Broeckel RM; Haese N; Ando T; Dmitriev I; Kreklywich CN; Powers J; Denton M; Smith P; Morrison TE; Heise M; DeFilippis V; Messaoudi I; Curiel DT; Streblow DN
Front Immunol; 2019; 10():2563. PubMed ID: 31736977
[TBL] [Abstract][Full Text] [Related]
15. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine.
Harro CD; Pang YY; Roden RB; Hildesheim A; Wang Z; Reynolds MJ; Mast TC; Robinson R; Murphy BR; Karron RA; Dillner J; Schiller JT; Lowy DR
J Natl Cancer Inst; 2001 Feb; 93(4):284-92. PubMed ID: 11181775
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity, safety, and tolerability of the measles-vectored chikungunya virus vaccine MV-CHIK: a double-blind, randomised, placebo-controlled and active-controlled phase 2 trial.
Reisinger EC; Tschismarov R; Beubler E; Wiedermann U; Firbas C; Loebermann M; Pfeiffer A; Muellner M; Tauber E; Ramsauer K
Lancet; 2019 Dec; 392(10165):2718-2727. PubMed ID: 30409443
[TBL] [Abstract][Full Text] [Related]
17. Antigenicity and immunogenicity of chikungunya virus-like particles from mosquito cells.
Tsai SK; Hsu YL; Chiao DJ; Shu PY; Lin HT; Chang SF; Lin HC; Huang SH; Wang CH; Hsiung CC; Lin CC; Wu TY; Kuo SC
Appl Microbiol Biotechnol; 2023 Jan; 107(1):219-232. PubMed ID: 36434113
[TBL] [Abstract][Full Text] [Related]
18. Effective chikungunya virus-like particle vaccine produced in insect cells.
Metz SW; Gardner J; Geertsema C; Le TT; Goh L; Vlak JM; Suhrbier A; Pijlman GP
PLoS Negl Trop Dis; 2013; 7(3):e2124. PubMed ID: 23516657
[TBL] [Abstract][Full Text] [Related]
19. Delta inulin-derived adjuvants that elicit Th1 phenotype following vaccination reduces respiratory syncytial virus lung titers without a reduction in lung immunopathology.
Wong TM; Petrovsky N; Bissel SJ; Wiley CA; Ross TM
Hum Vaccin Immunother; 2016 Aug; 12(8):2096-2105. PubMed ID: 27215855
[TBL] [Abstract][Full Text] [Related]
20. Whole-Inactivated and Virus-Like Particle Vaccine Strategies for Chikungunya Virus.
DeZure AD; Berkowitz NM; Graham BS; Ledgerwood JE
J Infect Dis; 2016 Dec; 214(suppl 5):S497-S499. PubMed ID: 27920180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
